Sign In
Buy SGIOY
$8.74
-0.0900 (-1.02%)
At Close: Jun 03, 2026
New England Journal of Medicine Publishes Shionogi Study Demonstrating Ensitrelvir Prevents COVID-19 Following Exposure
05:08pm, Wednesday, 13'th May 2026
OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, PhD; hereinafter “Shionogi”) announced that results from its global, double
OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced that Shionogi Inc., a New Jersey-bas
Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone)
07:30pm, Wednesday, 01'st Apr 2026
OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced that we have completed the transfer
SGIOY vs. SDZNY: Which Stock Is the Better Value Option?
12:41pm, Thursday, 26'th Mar 2026
Investors interested in Medical - Drugs stocks are likely familiar with Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) and Sandoz Group AG Sponsored ADR (SDZNY).
Shionogi Announces First Patients Enrolled in Global Phase 2 Clinical Trial in Adults with Late-Onset Pompe Disease
08:45am, Thursday, 19'th Mar 2026
OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced the first patients were enrolled in
SGIOY vs. SDZNY: Which Stock Should Value Investors Buy Now?
12:41pm, Tuesday, 10'th Mar 2026
Investors with an interest in Medical - Drugs stocks have likely encountered both Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) and Sandoz Group AG Sponsored ADR (SDZNY).
SGIOY or SDZNY: Which Is the Better Value Stock Right Now?
12:40pm, Thursday, 19'th Feb 2026
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) and Sandoz Group AG Sponsored ADR (SDZNY).
SGIOY vs. ZTS: Which Stock Is the Better Value Option?
12:40pm, Tuesday, 03'rd Feb 2026
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) and Zoetis (ZTS).
Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Hits New 12-Month High – Should You Buy?
05:08am, Sunday, 25'th Jan 2026
Shares of Shionogi and Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) hit a new 52-week high on Friday. The company traded as high as $9.85 and last traded at $9.8340, with a volume of 35
Analyzing Zoetis (NYSE:ZTS) and Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY)
03:44am, Saturday, 15'th Nov 2025
Zoetis (NYSE: ZTS - Get Free Report) and Shionogi and Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) are both large-cap medical companies, but which is the superior investment? We will co
Shionogi & Co., Ltd. (SGIOY) Q1 2025 Earnings Call Transcript
08:35am, Tuesday, 29'th Jul 2025
Shionogi & Co., Ltd. (OTCPK:SGIOY) Q1 2025 Earnings Conference Call July 28, 2025 3:30 AM ET Company Participants John A.
SGIOY or ZTS: Which Is the Better Value Stock Right Now?
12:41pm, Monday, 07'th Jul 2025
Investors looking for stocks in the Medical - Drugs sector might want to consider either Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) or Zoetis (ZTS).
SGIOY or ZTS: Which Is the Better Value Stock Right Now?
12:41pm, Friday, 20'th Jun 2025
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) and Zoetis (ZTS).
Shionogi & Co., Ltd. (SGIOY) Q3 2024 Earnings Call Transcript
10:53pm, Friday, 31'st Jan 2025
Shionogi & Co., Ltd. (OTCPK:SGIOY) Q3 2024 Earnings Conference Call January 31, 2025 3:30 AM ET Company Participants Yoshimasa Kyokawa - VP, Corporate Communications Masako Kudou - VP, Finance & Accou
Shionogi & Co. (SGIOY) Upgraded to Buy: What Does It Mean for the Stock?
01:00pm, Monday, 27'th Jan 2025
Shionogi & Co. (SGIOY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
